Zika virus (ZIKV) is an emerging pathogen that causes devastating congenital defects. The
overlapping epidemiology and immunologic cross-reactivity between ZIKV and dengue virus …

The Zika virus (ZIKV), a flavivirus transmitted by Aedes mosquitoes, has emerged as a
global public health concern. Pre-existing cross-reactive antibodies against other …

The 2015–2016 outbreak of Zika virus (ZIKV) disease has affected many countries and is a
major public health concern. ZIKV is associated with fetal microcephaly and neurological …

Recent epidemics of Zika virus (ZIKV) have been associated with congenital malformation
during pregnancy and Guillain-Barré syndrome. There are two ZIKV lineages (African and …

The recent Zika virus (ZIKV) epidemic in the Americas has revealed rare but serious
manifestations of infection. ZIKV has emerged in regions endemic for dengue virus (DENV) …

Zika virus (ZIKV) infection poses a serious threat to human health. However, no licensed
vaccine or therapeutic drug is currently available for ZIKV. We have previously shown that …

Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological
pathology and congenital neurologic defects. Rapid vaccine development has led to a …

Zika virus (ZIKV) specific neutralizing antibodies hold great promise for antibody-based
interventions and vaccine design against ZIKV infection. However, their development in …

The emergence of Zika virus (ZIKV) in the Americas stimulated the development of multiple
ZIKV vaccine candidates. We previously developed two related DNA vaccine candidates …

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in
individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil …